세포 및 유전자 치료용 콜드체인 물류 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 구성 요소, 제공 서비스, 유지 온도 범위, 최종사용자, 지역별 및 경쟁(2021-2031년)

Cell & Gene Therapy Cold Chain Logistics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Component, By Services Offered, By Holding Temperature Range, By End User, By Region & Competition, 2021-2031F

US $ 4,500 ￦ 6,722,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 8,215,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 11,950,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

세계의 세포·유전자 치료용 콜드체인 물류 시장은 2025년 20억 2,000만 달러에서 2031년까지 44억 7,000만 달러로 확대하며, CAGR 14.15%를 기록할 것으로 예측되고 있습니다.

이 분야는 치료용 생물학적 물질의 온도 관리된 취급, 보관, 운송에 특화된 공급망 서비스를 포함합니다. 이러한 물류 솔루션은 운송 중 극저온 조건을 자주 필요로 하는 온도에 민감하고 시간적 제약이 있는 세포 제품의 유효성을 유지하기 위해 필수적입니다. 이 시장을 촉진하는 주요 요인은 임상 개발 파이프라인의 급속한 확장과 이에 따른 규제 당국의 승인 건수 증가로 인해 안전한 세계 유통 네트워크의 필요성이 증가하고 있습니다. 국제세포-유전자치료학회(ISCT)의 보고서에 따르면 2024년 전 세계 치료제 파이프라인은 3,063개로 확대될 것으로 예상되며, 이러한 신흥 치료법에 대한 전문 물류 지원 수요가 크게 증가할 것으로 예측됩니다.

시장 개요
예측 기간	2027-2031
시장 규모 : 2025년	20억 2,000만 달러
시장 규모 : 2031년	44억 7,000만 달러
CAGR : 2026-2031년	14.15%
가장 빠르게 성장하는 부문	콜드체인 관리 시스템
최대 시장	북미

이러한 상승 추세에도 불구하고 복잡한 국제 밸류체인 전체에서 엄격한 온도 안정성을 유지하는 데 있으며, 시장은 큰 어려움에 직면해 있습니다. 초저온의 필요성은 특히 중요한 라스트 마일 배송 단계에서 온도 편차로 인한 제품 손실의 위험을 증가시킵니다. 또한 특정 지역의 인프라 부족은 콜드체인의 연속성을 방해하고 이러한 고가 치료제의 유통을 복잡하게 만들어 시장의 광범위한 세계 확장을 저해할 수 있습니다.

시장 성장 촉진요인

바이오의약품 연구개발에 대한 세계 투자 및 자금 조달이 증가함에 따라 임상 프로그램 확대 및 물류 요구사항에 대한 자금 조달을 통해 시장 성장을 가속하고 있습니다. 대규모 자금 유입을 통해 개발 기업은 중요한 프리미엄 온도 관리 공급망 서비스를 아웃소싱하여 민감한 생물학적 자산을 보호할 수 있게 됩니다. 2024년 10월 BioSpace의 기사 '어려운 수년간 세포 및 유전자 치료 투자 증가'에 따르면 이 분야는 2024년 상반기에 109억 달러의 투자를 유치했습니다. 이 자금은 광범위한 조사를 지원하고 전문적인 취급 수요를 촉진하고 있습니다. 예를 들어 Cryoport는 2024년 9월 30일 기준으로 역대 최다인 691건의 세계 임상시험을 지원했다고 보고했으며, 이는 이 자본이 주도하는 활발한 개발 활동을 강조합니다.

또한 세포 및 유전자 치료제의 상용화와 규제 승인이 가속화됨에 따라 업계의 초점은 임상 출하에서 대량 상업적 유통으로 옮겨가고 있습니다. 치료법이 승인됨에 따라 엄격한 기준을 준수하면서 전 세계 환자들에게 접근성을 보장하기 위해 물류 네트워크의 확장이 요구되고 있습니다. 상업화 단계로의 전환을 위해서는 고부가가치 치료를 손상시킬 수 있는 온도 편차를 방지하기 위한 엄격한 콜드체인 인프라가 필수적입니다. 2024년 10월 World Courier가 발표한 '2024년 3분기 CGT 파이프라인 주요 인사이트'에 따르면 현재 전 세계에서 승인된 세포 및 유전자 치료제는 134개에 달할 전망입니다. 이렇게 늘어나는 상업용 제품에는 초저온 요구 사항을 관리할 수 있는 강력한 유통 네트워크가 필요합니다.

시장이 해결해야 할 과제

세계 세포 및 유전자 치료 콜드체인 물류 시장의 주요 장벽은 복잡해지는 국제 밸류체인 전반에서 엄격한 온도 안정성을 유지하는 것이 어렵다는 점입니다. 이러한 고가 치료제는 초저온의 극저온 환경을 필요로 하는 경우가 많으며, 운송 중 온도 편차나 인프라 장애는 제품의 돌이킬 수 없는 손실로 이어집니다. 이러한 취약성은 콜드체인 체제가 미흡한 지역이나 라스트마일 배송 시간이 긴 지역으로의 유통에서 특히 심각하며, 시장 접근과 상업적 확장에 큰 장벽이 되고 있습니다.

이러한 물류 취약성의 영향은 산업의 세계 규모에 따라 더욱 증폭됩니다. 재생의료연합(Alliance for Regenerative Medicine)에 따르면 2025년 세포 및 유전자 치료의 전 세계 매출의 약 35%는 미국 이외 시장에서 창출될 것이라고 합니다. 이 통계는 이 부문의 경제적 가치의 상당 부분이 국경 간 운송에 크게 의존하고 있음을 보여줍니다. 그 결과, 다양한 지역적 상황별 온도 변화의 위험은 개발도상국 기업에게 재정적 불확실성을 가져와 시장 확대 전략에 제한을 가하고, 세계 물류 부문 전체의 성장을 직접적으로 둔화시키는 요인으로 작용하고 있습니다.

시장 동향

클라우드 기반 셀 오케스트레이션 플랫폼의 도입은 수동 추적 방식을 통합 디지털 생태계로 대체함으로써 업계를 변화시키고 있습니다. 자가치료가 확대됨에 따라 제조업체는 복잡한 워크플로우 전반에 걸쳐 아이덴티티 체인(Chain of Identity)을 유지하기 위해 정맥에서 정맥까지 실시간 가시성을 필요로 하고 있습니다. 이러한 디지털 전환은 인적 오류를 줄이고, 백혈구 분리(leukapheresis) 및 주입 스케줄을 효율화하여 생산 기지와 임상 센터를 효과적으로 연결합니다. 2024년 11월에 발표된 트랙셀의 '트랙셀, 새로운 기준을 세우다'에 따르면 트랙셀의 오케스트레이션 플랫폼은 2024년에 승인되었거나 승인을 앞두고 있는 7개의 자가 또는 동종 세포 치료 제품 중 5개를 지원하기 위해 선정되었습니다.

또한 바이오제약 기업이 고부가가치 상용 제품 유통에 따른 리스크를 줄이기 위해 전문성이 높은 틈새 물류업체에 대한 전략적 아웃소싱이 필수적인 요소로 떠오르고 있습니다. 표준 의약품 운송과 달리 세포-유전자치료(CGT) 물류는 극저온 듀어 용기 관리, 재생의료 규제 기준의 엄격한 준수 등 전용 인프라를 필요로 합니다. 개발사들은 제품의 완성도를 확보하기 위해 범용 화물 운송업체가 아닌 전용 기능을 보유한 벤더와의 협업을 강화하고 있습니다. Cryoport, Inc.가 2025년 3월 발표한 '2024년 4분기 및 연간 실적 보고서'에 따르면 상업적으로 승인된 세포 및 유전자 치료 제품 지원으로 인한 매출은 2024년 2,600만 달러에 달하고, 전년 대비 20% 증가했습니다.

목차

제1장 개요

제2장 조사 방법

제3장 개요

제4장 고객의 소리

제5장 세계의 세포·유전자 치료용 콜드체인 물류 시장 전망

제6장 북미의 세포·유전자 치료용 콜드체인 물류 시장 전망

제7장 유럽의 세포·유전자 치료용 콜드체인 물류 시장 전망

제8장 아시아태평양의 세포·유전자 치료용 콜드체인 물류 시장 전망

제9장 중동 및 아프리카의 세포·유전자 치료용 콜드체인 물류 시장 전망

제10장 남미의 세포·유전자 치료용 콜드체인 물류 시장 전망

제11장 시장 역학

제12장 시장 동향과 발전

제13장 세계의 세포·유전자 치료용 콜드체인 물류 시장 : SWOT 분석

제14장 Porter's Five Forces 분석

제15장 경쟁 구도

제16장 전략적 제안

제17장 조사회사 소개·면책사항

KSA

영문 목차

영문목차

The Global Cell & Gene Therapy Cold Chain Logistics Market is projected to expand from USD 2.02 Billion in 2025 to USD 4.47 Billion by 2031, registering a CAGR of 14.15%. This sector encompasses specialized supply chain services focused on the temperature-controlled handling, storage, and transport of therapeutic biological materials. These logistics solutions are vital for maintaining the efficacy of temperature-sensitive and time-critical cellular products, which frequently demand cryogenic conditions throughout transit. A major factor driving this market is the rapid growth of the clinical development pipeline and the resulting rise in regulatory approvals, creating a need for secure global distribution networks. As reported by the International Society for Cell & Gene Therapy, the global sector pipeline expanded to 3,063 therapies in 2024, generating significant demand for specialized logistical support for these emerging treatments.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 2.02 Billion
Market Size 2031	USD 4.47 Billion
CAGR 2026-2031	14.15%
Fastest Growing Segment	Cold Chain Management Systems
Largest Market	North America

Despite this upward trajectory, the market encounters substantial difficulties in maintaining strict temperature stability across intricate international supply chains. The necessity for ultra-low temperatures poses a high risk of product loss due to potential temperature excursions, especially during the critical last-mile delivery stage. Additionally, infrastructure deficiencies in specific geographic areas can interrupt the cold chain's continuity, complicating the distribution of these high-value therapeutics and potentially hindering the market's broader global expansion.

Market Driver

The rise in global investments and funding for biopharmaceutical R&D drives market growth by financing expanded clinical programs and their logistical requirements. Substantial capital inflows allow developers to outsource essential, premium temperature-controlled supply chain services to protect sensitive biological assets. According to an October 2024 BioSpace article titled 'Cell and Gene Therapy Investment Ticks Up After Hard Few Years', the sector secured $10.9 billion in investment during the first half of 2024. This funding supports extensive research and drives demand for specialized handling; for instance, Cryoport, Inc. reported supporting a record 691 global clinical trials as of September 30, 2024, highlighting the intense development activity driven by this capital.

Furthermore, the accelerating commercialization and regulatory approval of cell and gene therapies are shifting the industry's focus from clinical shipments to high-volume commercial distribution. As therapies receive authorization, logistics networks must expand to guarantee global patient access while adhering to strict standards. Transitioning to commercial stages requires rigorous cold chain infrastructure to prevent temperature excursions that could compromise high-value treatments. According to World Courier's 'CGT pipeline key insights for 2024 Q3' published in October 2024, there are now 134 cell and gene therapies approved globally. This growing number of commercial products demands robust distribution networks capable of managing ultra-low temperature requirements.

Market Challenge

The primary obstacle hindering the Global Cell & Gene Therapy Cold Chain Logistics Market is the complexity of maintaining rigorous temperature stability throughout increasingly intricate international supply chains. Because these high-value therapeutics frequently demand ultra-low cryogenic temperatures, any thermal excursion or infrastructure failure during transit can lead to irreversible product loss. This fragility is especially damaging when distributing to regions with unreliable cold chain capabilities or extended last-mile delivery durations, serving as a significant barrier to market accessibility and commercial scaling.

The consequences of this logistical vulnerability are greatly intensified by the industry's global scope. According to the Alliance for Regenerative Medicine, approximately 35 percent of global revenue from cell and gene therapy in 2025 originated from markets outside the United States. This statistic highlights that a significant portion of the sector's economic value depends heavily on cross-border transport. As a result, the risk of temperature deviations across diverse geographic landscapes generates financial uncertainty for developers, compelling them to restrict market expansion strategies and directly slowing the broader growth of the global logistics sector.

Market Trends

The deployment of cloud-based cell orchestration platforms is transforming the sector by substituting manual tracking methods with integrated digital ecosystems. As autologous therapies scale, manufacturers need real-time vein-to-vein visibility to guarantee the preservation of the Chain of Identity across complex workflows. This digital transition reduces human error and streamlines the scheduling of leukapheresis and infusion, effectively connecting manufacturing sites with clinical centers. According to TrakCel's 'TrakCel Sets New Standards' announcement in November 2024, the company's orchestration platform was chosen to support five out of the seven autologous or matched allogeneic cell therapy products approved or anticipated for approval in 2024.

Additionally, strategic outsourcing to specialized niche logistics providers is becoming essential as biopharmaceutical companies aim to reduce the risks associated with distributing high-value commercial products. Unlike standard pharmaceutical shipping, CGT logistics require dedicated infrastructure, such as fleet management for cryogenic dewars and strict compliance with regenerative medicine regulatory standards. Developers are increasingly collaborating with vendors that offer purpose-built capabilities rather than generalist freight forwarders to ensure product integrity. According to Cryoport, Inc.'s 'Fourth Quarter and Full Year 2024 Financial Results' from March 2025, revenue from supporting commercially approved cell and gene therapies grew to $26 million in 2024, representing a 20 percent year-over-year increase.

Key Market Players

• Cencora, Inc.
• United Parcel Service, Inc.
• Catalent, Inc.
• BioLife Solutions, Inc.
• Cryoport System LLC.
• Atelerix Ltd.
• Life Science Group Ltd
• Yourway Biopharma Services Company
• Bertelsmann SE & Co. KGaA
• NMDP BioTherapies

Report Scope

In this report, the Global Cell & Gene Therapy Cold Chain Logistics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cell & Gene Therapy Cold Chain Logistics Market, By Component

• Cryogenic Shippers
• Cryogenic Storage Freezers
• Ultra Low Freezers
• Cold Chain Management Systems
• Shipment and Storage Medium
• Cryogenic Packout Kits
• Others

Cell & Gene Therapy Cold Chain Logistics Market, By Services Offered

• Transportation
• Storage
• Packaging

Cell & Gene Therapy Cold Chain Logistics Market, By Mode of Transportation

• Air
• Ground
• Water

Cell & Gene Therapy Cold Chain Logistics Market, By Holding Temperature Range

• Cryogenic
• Refrigerated
• Ambient
• Others

Cell & Gene Therapy Cold Chain Logistics Market, By End User

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Others

Cell & Gene Therapy Cold Chain Logistics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cell & Gene Therapy Cold Chain Logistics Market.

Available Customizations:

Global Cell & Gene Therapy Cold Chain Logistics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cell & Gene Therapy Cold Chain Logistics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Component (Cryogenic Shippers, Cryogenic Storage Freezers, Ultra Low Freezers, Cold Chain Management Systems, Shipment and Storage Medium, Cryogenic Packout Kits, Others)
  • 5.2.2. By Services Offered (Transportation, Storage, Packaging)
  • 5.2.3. By Mode of Transportation (Air, Ground, Water)
  • 5.2.4. By Holding Temperature Range (Cryogenic, Refrigerated, Ambient, Others)
  • 5.2.5. By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2025)
• 5.3. Market Map

6. North America Cell & Gene Therapy Cold Chain Logistics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Component
  • 6.2.2. By Services Offered
  • 6.2.3. By Mode of Transportation
  • 6.2.4. By Holding Temperature Range
  • 6.2.5. By End User
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Cell & Gene Therapy Cold Chain Logistics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Component
      • 6.3.1.2.2. By Services Offered
      • 6.3.1.2.3. By Mode of Transportation
      • 6.3.1.2.4. By Holding Temperature Range
      • 6.3.1.2.5. By End User
  • 6.3.2. Canada Cell & Gene Therapy Cold Chain Logistics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Component
      • 6.3.2.2.2. By Services Offered
      • 6.3.2.2.3. By Mode of Transportation
      • 6.3.2.2.4. By Holding Temperature Range
      • 6.3.2.2.5. By End User
  • 6.3.3. Mexico Cell & Gene Therapy Cold Chain Logistics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Component
      • 6.3.3.2.2. By Services Offered
      • 6.3.3.2.3. By Mode of Transportation
      • 6.3.3.2.4. By Holding Temperature Range
      • 6.3.3.2.5. By End User

7. Europe Cell & Gene Therapy Cold Chain Logistics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Component
  • 7.2.2. By Services Offered
  • 7.2.3. By Mode of Transportation
  • 7.2.4. By Holding Temperature Range
  • 7.2.5. By End User
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Cell & Gene Therapy Cold Chain Logistics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Component
      • 7.3.1.2.2. By Services Offered
      • 7.3.1.2.3. By Mode of Transportation
      • 7.3.1.2.4. By Holding Temperature Range
      • 7.3.1.2.5. By End User
  • 7.3.2. France Cell & Gene Therapy Cold Chain Logistics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Component
      • 7.3.2.2.2. By Services Offered
      • 7.3.2.2.3. By Mode of Transportation
      • 7.3.2.2.4. By Holding Temperature Range
      • 7.3.2.2.5. By End User
  • 7.3.3. United Kingdom Cell & Gene Therapy Cold Chain Logistics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Component
      • 7.3.3.2.2. By Services Offered
      • 7.3.3.2.3. By Mode of Transportation
      • 7.3.3.2.4. By Holding Temperature Range
      • 7.3.3.2.5. By End User
  • 7.3.4. Italy Cell & Gene Therapy Cold Chain Logistics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Component
      • 7.3.4.2.2. By Services Offered
      • 7.3.4.2.3. By Mode of Transportation
      • 7.3.4.2.4. By Holding Temperature Range
      • 7.3.4.2.5. By End User
  • 7.3.5. Spain Cell & Gene Therapy Cold Chain Logistics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Component
      • 7.3.5.2.2. By Services Offered
      • 7.3.5.2.3. By Mode of Transportation
      • 7.3.5.2.4. By Holding Temperature Range
      • 7.3.5.2.5. By End User

8. Asia Pacific Cell & Gene Therapy Cold Chain Logistics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Component
  • 8.2.2. By Services Offered
  • 8.2.3. By Mode of Transportation
  • 8.2.4. By Holding Temperature Range
  • 8.2.5. By End User
  • 8.2.6. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Cell & Gene Therapy Cold Chain Logistics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Component
      • 8.3.1.2.2. By Services Offered
      • 8.3.1.2.3. By Mode of Transportation
      • 8.3.1.2.4. By Holding Temperature Range
      • 8.3.1.2.5. By End User
  • 8.3.2. India Cell & Gene Therapy Cold Chain Logistics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Component
      • 8.3.2.2.2. By Services Offered
      • 8.3.2.2.3. By Mode of Transportation
      • 8.3.2.2.4. By Holding Temperature Range
      • 8.3.2.2.5. By End User
  • 8.3.3. Japan Cell & Gene Therapy Cold Chain Logistics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Component
      • 8.3.3.2.2. By Services Offered
      • 8.3.3.2.3. By Mode of Transportation
      • 8.3.3.2.4. By Holding Temperature Range
      • 8.3.3.2.5. By End User
  • 8.3.4. South Korea Cell & Gene Therapy Cold Chain Logistics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Component
      • 8.3.4.2.2. By Services Offered
      • 8.3.4.2.3. By Mode of Transportation
      • 8.3.4.2.4. By Holding Temperature Range
      • 8.3.4.2.5. By End User
  • 8.3.5. Australia Cell & Gene Therapy Cold Chain Logistics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Component
      • 8.3.5.2.2. By Services Offered
      • 8.3.5.2.3. By Mode of Transportation
      • 8.3.5.2.4. By Holding Temperature Range
      • 8.3.5.2.5. By End User

9. Middle East & Africa Cell & Gene Therapy Cold Chain Logistics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Component
  • 9.2.2. By Services Offered
  • 9.2.3. By Mode of Transportation
  • 9.2.4. By Holding Temperature Range
  • 9.2.5. By End User
  • 9.2.6. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Cell & Gene Therapy Cold Chain Logistics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Component
      • 9.3.1.2.2. By Services Offered
      • 9.3.1.2.3. By Mode of Transportation
      • 9.3.1.2.4. By Holding Temperature Range
      • 9.3.1.2.5. By End User
  • 9.3.2. UAE Cell & Gene Therapy Cold Chain Logistics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Component
      • 9.3.2.2.2. By Services Offered
      • 9.3.2.2.3. By Mode of Transportation
      • 9.3.2.2.4. By Holding Temperature Range
      • 9.3.2.2.5. By End User
  • 9.3.3. South Africa Cell & Gene Therapy Cold Chain Logistics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Component
      • 9.3.3.2.2. By Services Offered
      • 9.3.3.2.3. By Mode of Transportation
      • 9.3.3.2.4. By Holding Temperature Range
      • 9.3.3.2.5. By End User

10. South America Cell & Gene Therapy Cold Chain Logistics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Component
  • 10.2.2. By Services Offered
  • 10.2.3. By Mode of Transportation
  • 10.2.4. By Holding Temperature Range
  • 10.2.5. By End User
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Cell & Gene Therapy Cold Chain Logistics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Component
      • 10.3.1.2.2. By Services Offered
      • 10.3.1.2.3. By Mode of Transportation
      • 10.3.1.2.4. By Holding Temperature Range
      • 10.3.1.2.5. By End User
  • 10.3.2. Colombia Cell & Gene Therapy Cold Chain Logistics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Component
      • 10.3.2.2.2. By Services Offered
      • 10.3.2.2.3. By Mode of Transportation
      • 10.3.2.2.4. By Holding Temperature Range
      • 10.3.2.2.5. By End User
  • 10.3.3. Argentina Cell & Gene Therapy Cold Chain Logistics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Component
      • 10.3.3.2.2. By Services Offered
      • 10.3.3.2.3. By Mode of Transportation
      • 10.3.3.2.4. By Holding Temperature Range
      • 10.3.3.2.5. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Cell & Gene Therapy Cold Chain Logistics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Cencora, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. United Parcel Service, Inc.
• 15.3. Catalent, Inc.
• 15.4. BioLife Solutions, Inc.
• 15.5. Cryoport System LLC.
• 15.6. Atelerix Ltd.
• 15.7. Life Science Group Ltd
• 15.8. Yourway Biopharma Services Company
• 15.9. Bertelsmann SE & Co. KGaA
• 15.10. NMDP BioTherapies

16. Strategic Recommendations

17. About Us & Disclaimer

관련자료